efinaconazole 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
systemic antifungal agents, miconazole derivatives 4874 164650-44-6

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • efinaconazole
  • jublia
  • KP-103
Efinaconazole is an azole antifungal. Efinaconazole inhibits fungal lanosterol 14α-demethylase involved in the biosynthesis of ergosterol, a constituent of fungal cell membranes.
  • Molecular weight: 348.40
  • Formula: C18H22F2N4O
  • CLOGP: 2.42
  • LIPINSKI: 0
  • HAC: 5
  • HDO: 1
  • TPSA: 54.18
  • ALOGS: -2.76
  • ROTB: 5
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
kinase-safety-class ACVR2B,BRAF,CDK5,EIF2AK3,GRK2,NTRK2,PDK1,PDK2,PDK4,TGFBR1 10
pfas-class PFAS structural alert (1 = True, 0 = False) 0

Approvals:

DateAgencyCompanyOrphan
July 4, 2014 PMDA
June 6, 2014 FDA DOW PHARM

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Bronchopulmonary aspergillosis allergic 317.30 37.96 66 4754 3700 90619927
Lung opacity 285.57 37.96 66 4754 6036 90617591
Total lung capacity decreased 265.21 37.96 57 4763 3738 90619889
Blood calcium increased 240.93 37.96 66 4754 11992 90611635
Aspiration 228.12 37.96 67 4753 15626 90608001
Rales 223.17 37.96 66 4754 15761 90607866
Sputum discoloured 206.69 37.96 66 4754 20325 90603302
Blood test abnormal 204.93 37.96 66 4754 20886 90602741
Bronchiectasis 200.80 37.96 66 4754 22264 90601363
Obstructive airways disorder 191.27 37.96 66 4754 25803 90597824
Haemoptysis 174.96 37.96 66 4754 33254 90590373
Transaminases increased 167.90 37.96 66 4754 37126 90586501
Pleuritic pain 136.02 37.96 41 4779 10420 90613207
Hypoxia 125.79 37.96 66 4754 72333 90551294
Pulmonary mass 119.15 37.96 48 4772 28724 90594903
Liver function test increased 118.67 37.96 67 4753 84788 90538839
Blood creatinine increased 107.61 37.96 67 4753 101319 90522308
Pulmonary fibrosis 101.54 37.96 66 4754 107437 90516190
Upper respiratory tract infection 93.24 37.96 67 4753 128251 90495376
Pleural effusion 87.19 37.96 61 4759 111930 90511697
Gastrooesophageal reflux disease 86.12 37.96 71 4749 166266 90457361
Tremor 84.81 37.96 68 4752 153105 90470522
Oedema peripheral 77.03 37.96 81 4739 257834 90365793
Obstructive defaecation 68.77 37.96 12 4808 258 90623369
Stoma site dermatitis 68.08 37.96 12 4808 274 90623353
Pneumococcal infection 66.43 37.96 15 4805 1230 90622397
Gastrointestinal stoma output abnormal 63.47 37.96 12 4808 408 90623219
Cough 58.20 37.96 84 4736 368878 90254749
Asthma 56.67 37.96 67 4753 242093 90381534
Stoma site inflammation 56.16 37.96 12 4808 762 90622865
Lower respiratory tract infection 53.19 37.96 66 4754 250593 90373034
Constipation 51.92 37.96 69 4751 280326 90343301
Asthenia 51.07 37.96 97 4723 533654 90089973
Underweight 49.16 37.96 12 4808 1378 90622249
Stoma site pain 48.93 37.96 12 4808 1405 90622222
Product dose omission issue 45.35 37.96 66 4754 291621 90332006
Musculoskeletal stiffness 44.51 37.96 66 4754 296466 90327161
Gastrointestinal stoma complication 42.57 37.96 12 4808 2407 90621220
Wheezing 41.62 37.96 57 4763 238023 90385604
Abdominal pain upper 41.51 37.96 68 4752 332606 90291021
Hiccups 39.92 37.96 12 4808 3014 90620613
Faeces hard 39.10 37.96 12 4808 3230 90620397
Anaemia 38.57 37.96 68 4752 352734 90270893
Metabolic alkalosis 38.03 37.96 12 4808 3537 90620090
Osteogenesis imperfecta 37.99 37.96 9 4811 911 90622716

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Bronchopulmonary aspergillosis allergic 132.90 63.71 37 3493 4561 42613244
Congenital hiatus hernia 126.43 63.71 38 3492 6136 42611669
Anticoagulant therapy 115.23 63.71 33 3497 4502 42613303
Antacid therapy 113.94 63.71 33 3497 4684 42613121
Sleep disorder therapy 113.93 63.71 36 3494 6858 42610947
Analgesic therapy 111.69 63.71 35 3495 6489 42611316
Blood calcium increased 106.72 63.71 36 3494 8418 42609387
Hyperphosphataemia 102.27 63.71 39 3491 12965 42604840
Drug therapy 99.99 63.71 32 3498 6348 42611457
Activated partial thromboplastin time prolonged 98.07 63.71 40 3490 15863 42601942
Pleuritic pain 92.73 63.71 31 3499 7046 42610759
Myasthenia gravis 90.73 63.71 38 3492 16099 42601706
Blood test abnormal 88.34 63.71 35 3495 12871 42604934
Hypophosphataemia 84.33 63.71 39 3491 20906 42596899
Aspiration 83.73 63.71 37 3493 17849 42599956
Breath sounds abnormal 79.99 63.71 32 3498 12061 42605744
Bacterial infection 79.47 63.71 41 3489 27838 42589967
Micturition urgency 77.02 63.71 31 3499 11867 42605938
End stage renal disease 76.68 63.71 34 3496 16524 42601281
Incorrect route of product administration 75.84 63.71 38 3492 24267 42593538
Neuralgia 73.91 63.71 38 3492 25609 42592196
Joint injury 70.75 63.71 31 3499 14645 42603160
Ulcer 70.52 63.71 32 3498 16409 42601396
Hyperlipidaemia 68.18 63.71 34 3496 21482 42596323
Hypercholesterolaemia 64.73 63.71 28 3502 12821 42604984

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Bronchopulmonary aspergillosis allergic 441.60 43.09 107 8329 8319 110572544
Blood calcium increased 356.51 43.09 106 8330 17934 110562929
Aspiration 309.35 43.09 108 8328 30425 110550438
Total lung capacity decreased 305.43 43.09 77 8359 7037 110573826
Blood test abnormal 304.73 43.09 105 8331 28449 110552414
Lung opacity 290.29 43.09 82 8354 11570 110569293
Pleuritic pain 234.77 43.09 75 8361 16065 110564798
Rales 233.33 43.09 83 8353 24656 110556207
Sputum discoloured 223.46 43.09 83 8353 27862 110553001
Transaminases increased 214.39 43.09 102 8334 63288 110517575
Bronchiectasis 201.95 43.09 83 8353 36410 110544453
Obstructive airways disorder 183.20 43.09 83 8353 46066 110534797
Upper respiratory tract infection 161.78 43.09 109 8327 131219 110449644
Haemoptysis 148.94 43.09 83 8353 71271 110509592
Pulmonary mass 141.44 43.09 65 8371 37236 110543627
Blood creatinine increased 135.81 43.09 112 8324 182777 110398086
Liver function test increased 134.84 43.09 84 8352 88464 110492399
Congenital hiatus hernia 133.28 43.09 39 8397 6220 110574643
Pulmonary fibrosis 123.94 43.09 84 8352 101958 110478905
Sleep disorder therapy 122.25 43.09 38 8398 7433 110573430
Anticoagulant therapy 121.21 43.09 35 8401 5326 110575537
Antacid therapy 120.43 43.09 35 8401 5449 110575414
Tremor 120.07 43.09 109 8327 202123 110378740
Analgesic therapy 118.98 43.09 37 8399 7247 110573616
Drug therapy 106.47 43.09 34 8402 7257 110573606
Lower respiratory tract infection 104.88 43.09 110 8326 242996 110337867
Hypoxia 103.85 43.09 83 8353 129432 110451431
Hyperphosphataemia 103.47 43.09 41 8395 16340 110564523
Asthma 98.71 43.09 108 8328 250183 110330680
Oedema peripheral 96.67 43.09 122 8314 328538 110252325
Activated partial thromboplastin time prolonged 94.34 43.09 42 8394 22326 110558537
Gastrooesophageal reflux disease 89.55 43.09 88 8348 179888 110400975
Myasthenia gravis 89.47 43.09 40 8396 21471 110559392
Musculoskeletal stiffness 88.89 43.09 108 8328 279714 110301149
Pleural effusion 81.24 43.09 83 8353 177626 110403237
Product dose omission issue 76.97 43.09 108 8328 321674 110259189
End stage renal disease 76.95 43.09 36 8400 21437 110559426
Hypophosphataemia 73.02 43.09 40 8396 33142 110547721
Benign prostatic hyperplasia 72.95 43.09 33 8403 18201 110562662
Neuralgia 68.76 43.09 44 8392 48434 110532429
Bacterial infection 68.32 43.09 43 8393 45993 110534870
Micturition urgency 68.02 43.09 32 8404 19288 110561575
Breath sounds abnormal 65.40 43.09 34 8402 25370 110555493
Obstructive defaecation 64.80 43.09 12 8424 250 110580613
Stoma site dermatitis 63.22 43.09 12 8424 287 110580576
Hyperlipidaemia 62.19 43.09 37 8399 35811 110545052
Drug hypersensitivity 61.69 43.09 118 8318 453972 110126891
Gout 58.93 43.09 36 8400 36530 110544333
Gastrointestinal stoma output abnormal 58.81 43.09 12 8424 420 110580443
Troponin increased 57.65 43.09 33 8403 29733 110551130
Respiratory symptom 56.48 43.09 26 8410 14919 110565944
Asthenia 56.25 43.09 146 8290 688853 109892010
Pneumococcal infection 55.40 43.09 15 8421 1804 110579059
Ulcer 51.12 43.09 35 8401 43081 110537782
Stress 49.54 43.09 50 8386 105298 110475565
Incorrect route of product administration 49.05 43.09 40 8396 64021 110516842
Cardiovascular disorder 48.87 43.09 27 8409 22733 110558130
Stoma site inflammation 48.37 43.09 12 8424 1023 110579840
Cough 47.44 43.09 107 8329 461534 110119329
Constipation 47.34 43.09 92 8344 357694 110223169
Wheezing 47.16 43.09 76 8360 255154 110325709
Joint injury 46.31 43.09 32 8404 39962 110540901
Underweight 43.72 43.09 12 8424 1518 110579345

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC D01AC19 DERMATOLOGICALS
ANTIFUNGALS FOR DERMATOLOGICAL USE
ANTIFUNGALS FOR TOPICAL USE
Imidazole and triazole derivatives
FDA CS M0002083 Azoles
FDA EPC N0000175487 Azole Antifungal
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000935 Antifungal Agents
CHEBI has role CHEBI:77884 EC 1.14.13.70 (sterol 14α-demethylase) inhibitor

Related Drugs by ATC class:

D01AC Imidazole and triazole derivatives 20 drugs
bifonazolechlormidazoleclotrimazoleeberconazoleeconazolefenticonazolefluconazoleflutrimazoleisoconazoleketoconazolelanoconazoleluliconazole show all 20 →

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Onychomycosis due to Trichophyton mentagrophytes indication 23549005
Onychomycosis due to dermatophyte indication 402134005
Onychomycosis of toenails indication 403059006




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 13.3 acidic
pKa2 7.37 Basic
pKa3 1.38 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
10% JUBLIA BAUSCH N203567 June 6, 2014 RX SOLUTION TOPICAL 7214506 Feb. 22, 2026 ANTIMYCOTIC USES, SPECIFICALLY TREATMENT OF ONYCHOMYCOSIS
10% JUBLIA BAUSCH N203567 June 6, 2014 RX SOLUTION TOPICAL 10512640 Jan. 3, 2028 TOPICAL TREATMENT OF ONYCHOMYCOSIS OF THE TOENAIL(S) DUE TO TRICHOPHYTON RUBRUM AND TRICHOPHYTON MENTAGROPHYTES
10% JUBLIA BAUSCH N203567 June 6, 2014 RX SOLUTION TOPICAL 11213519 Jan. 3, 2028 ANTIMYCOTIC USES, SPECIFICALLY TREATMENT OF ONYCHOMYCOSIS; TOPICAL TREATMENT OF THE TOENAIL(S) DUE TO TRICHOPHYTON RUBRUM AND TRICHOPHYTON MENTAGROPHYTES
10% JUBLIA BAUSCH N203567 June 6, 2014 RX SOLUTION TOPICAL 11872218 Jan. 3, 2028 TOPICAL TREATMENT OF ONYCHOMYCOSIS OF THE TOENAIL(S) DUE TO TRICHOPHYTON RUBRUM AND TRICHOPHYTON MENTAGROPHYTES
10% JUBLIA BAUSCH N203567 June 6, 2014 RX SOLUTION TOPICAL 9566272 Jan. 3, 2028 TOPICAL TREATMENT OF ONYCHOMYCOSIS OF THE TOENAIL(S) DUE TO TRICHOPHYTON RUBRUM AND TRICHOPHYTON MENTAGROPHYTES
10% JUBLIA BAUSCH N203567 June 6, 2014 RX SOLUTION TOPICAL 9877955 Jan. 3, 2028 TOPICAL TREATMENT OF ONYCHOMYCOSIS OF THE TOENAIL(S) DUE TO TRICHOPHYTON RUBRUM AND TRICHOPHYTON MENTAGROPHYTES
10% JUBLIA BAUSCH N203567 June 6, 2014 RX SOLUTION TOPICAL 8039494 July 8, 2030 ANTIMYCOTIC USES, SPECIFICALLY TREATMENT OF ONYCHOMYCOSIS
10% JUBLIA BAUSCH N203567 June 6, 2014 RX SOLUTION TOPICAL 10342875 Oct. 2, 2034 ANTIMYCOTIC USES, SPECIFICALLY TREATMENT OF ONYCHOMYCOSIS; TOPICAL TREATMENT OF THE TOENAIL(S) DUE TO TRICHOPHYTON RUBRUM AND TRICHOPHYTON MENTAGROPHYTES
10% JUBLIA BAUSCH N203567 June 6, 2014 RX SOLUTION TOPICAL 10828293 Oct. 2, 2034 ANTIMYCOTIC USES, SPECIFICALLY TREATMENT OF ONYCHOMYCOSIS; TOPICAL TREATMENT OF THE TOENAIL(S) DUE TO TRICHOPHYTON RUBRUM AND TRICHOPHYTON MENTAGROPHYTES
10% JUBLIA BAUSCH N203567 June 6, 2014 RX SOLUTION TOPICAL 10864274 Oct. 2, 2034 ANTIMYCOTIC USES, SPECIFICALLY TREATMENT OF ONYCHOMYCOSIS; TOPICAL TREATMENT OF THE TOENAIL(S) DUE TO TRICHOPHYTON RUBRUM AND TRICHOPHYTON MENTAGROPHYTES
10% JUBLIA BAUSCH N203567 June 6, 2014 RX SOLUTION TOPICAL 11654139 Oct. 2, 2034 TOPICAL TREATMENT OF ONYCHOMYCOSIS OF THE TOENAIL(S) DUE TO TRICHOPHYTON RUBRUM AND TRICHOPHYTON MENTAGROPHYTES
10% JUBLIA BAUSCH N203567 June 6, 2014 RX SOLUTION TOPICAL 10478601 April 25, 2035 TOPICAL TREATMENT OF TINEA UNGUIUM BY USING AN APPLICATOR FOR APPLYING A SOLUTION FOR TREATING TINEA UNGUIUM TO AN AFFECTED PART OF A PATIENT

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Lanosterol 14-alpha demethylase Enzyme INHIBITOR CHEMBL CHEMBL

External reference:

IDSource
D10021 KEGG_DRUG
4033415 VUID
N0000190763 NUI
4033415 VANDF
CHEBI:82718 CHEBI
CHEMBL2103877 ChEMBL_ID
C431707 MESH_SUPPLEMENTAL_RECORD_UI
DB09040 DRUGBANK_ID
1539753 RXNORM
221737 MMSL
30345 MMSL
015550 NDDF
703880007 SNOMEDCT_US
703881006 SNOMEDCT_US
C3273754 UMLSCUI
9349 INN_ID
489181 PUBCHEM_CID
J82SB7FXWB UNII

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
JUBLIA HUMAN PRESCRIPTION DRUG LABEL 1 0187-5400 SOLUTION 100 mg TOPICAL NDA 27 sections